The go-to provider of cell engineering solutions
We are a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development.
Built upon decades of experience in the engineering of cell lines, we have created a unique and high value portfolio of tools and services, which enable almost any gene to be altered or its function modulated, in human and other mammalian cell lines.
Our offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine.
Our latest results at a glance
-
Group revenue
£58.3m
Increase by 7.8%
-
Adjusted EBITDA
£3.9m
-
Group gross margin
70.0%
-
Cash
£18.8m
“Our goal is to leverage our expertise in gene editing and modulation to provide customers with tools and services to transform human health.”
Our latest annual report
Latest news
OUR GROUP AT GLANCE
A world-leader in the design, manufacture application of gene editing and gene modulation tools in life science market.
-
Employees
416
-
Countries
12
-
PHDs
> 85
-
Customers
> 2000
How we create value
We are focused on commercialising the application of gene editing and gene modulation technologies to accelerate scientific innovation and biopharmaceutical drug development
Our strategy
Our mission is to leverage our expertise in innovative gene editing and gene modulation applications to provide customers with tools and services to transform human health.